OBJECTIVES: To determine the value of loss of the expression of E-cadherin and cadherin-associated molecules as useful markers for both prognosis and bladder recurrence in patients with upper urinary tract cancer. MATERIALS AND METHODS: In 61 paraffin-embedded nephroureterectomy specimens, the expression of E-cadherin and alpha-, beta-, and gamma-catenin was examined by immunohistochemical staining. To evaluate the prognostic significance, Kaplan-Meier survival curves were calculated and compared by the log-rank test. A multivariate test was performed to detect prognostic markers. RESULTS: Normal expression was found in 32 cases (52.5%) for E-cadherin, 41 cases (67.2%) for alpha-catenin, 42 cases (68.9%) for beta-catenin, and 31 cases (50.8%) for gamma-catenin. The expression patterns of E-cadherin and alpha-, beta- and gamma-catenin were significantly correlated with each other. Survival analysis showed a significant difference between normal and aberrant expression in each staining. Multivariate analysis revealed that tumor stage and the expression of E-cadherin were independent prognostic factors for cause-specific survival. In contrast, there was no significant correlation between the expression of E-cadherin and alpha-, beta-, and gamma-catenin and bladder recurrence. CONCLUSION: Our data suggest E-cadherin may be a good prognostic marker for patients with upper urinary tract cancer.
OBJECTIVES: To determine the value of loss of the expression of E-cadherin and cadherin-associated molecules as useful markers for both prognosis and bladder recurrence in patients with upper urinary tract cancer. MATERIALS AND METHODS: In 61 paraffin-embedded nephroureterectomy specimens, the expression of E-cadherin and alpha-, beta-, and gamma-catenin was examined by immunohistochemical staining. To evaluate the prognostic significance, Kaplan-Meier survival curves were calculated and compared by the log-rank test. A multivariate test was performed to detect prognostic markers. RESULTS: Normal expression was found in 32 cases (52.5%) for E-cadherin, 41 cases (67.2%) for alpha-catenin, 42 cases (68.9%) for beta-catenin, and 31 cases (50.8%) for gamma-catenin. The expression patterns of E-cadherin and alpha-, beta- and gamma-catenin were significantly correlated with each other. Survival analysis showed a significant difference between normal and aberrant expression in each staining. Multivariate analysis revealed that tumor stage and the expression of E-cadherin were independent prognostic factors for cause-specific survival. In contrast, there was no significant correlation between the expression of E-cadherin and alpha-, beta-, and gamma-catenin and bladder recurrence. CONCLUSION: Our data suggest E-cadherin may be a good prognostic marker for patients with upper urinary tract cancer.
Authors: Kristopher R Koch; Chen-Ou Zhang; Piotr Kaczmarek; Joseph Barchi; Li Guo; Hanief M Shahjee; Susan Keay Journal: Invest New Drugs Date: 2011-09-20 Impact factor: 3.850
Authors: Maha Hussain; Stephanie Daignault; Neeraj Agarwal; Petros D Grivas; Arlene O Siefker-Radtke; Igor Puzanov; Gary R MacVicar; Ellis Glenn Levine; Sandy Srinivas; Przemyslaw Twardowski; Mario A Eisenberger; David I Quinn; Ulka N Vaishampayan; Evan Y Yu; Scott Dawsey; Kathleen C Day; Mark L Day; Mahmoud Al-Hawary; David C Smith Journal: Cancer Date: 2014-05-06 Impact factor: 6.860
Authors: I Ahmad; J P Morton; L B Singh; S M Radulescu; R A Ridgway; S Patel; J Woodgett; D J Winton; M M Taketo; X-R Wu; H Y Leung; O J Sansom Journal: Oncogene Date: 2010-09-06 Impact factor: 9.867
Authors: Laura Izquierdo; Ruth Montalbo; Mercedes Ingelmo-Torres; Carme Mallofré; Miguel Ramírez-Backhaus; Jose Rubio; Antoine G Van der Heijden; Ewout Schaafsma; Antonio Lopez-Beltran; Ana Blanca; Nathan Lawrentschuk; Antonio Alcaraz; Lourdes Mengual Journal: Oncotarget Date: 2017-05-16